OHRP News Alert Ohr Pharmaceutical Inc (OHRP) 7.45 11/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 6:14 PM

Ohr Pharmaceutical Inc (OHRP) 7.45 $OHRP

Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
GlobeNewswire - Mon Oct 27, 7:01AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst breakfast on Friday, October 31, 2014 from 8:00 am-9:30 am Eastern Time in New York City. The meeting will feature discussions by two retinal disease experts, K. Bailey Freund, M.D., and Ohr's Chief Medical Officer, Jason S. Slakter, MD.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Mon Oct 20, 6:15AM CDT
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
OHRP: 7.45 (+0.18)

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents
at The Street - Fri Oct 17, 6:05AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
AVNR: 13.14 (-0.04), OHRP: 7.45 (+0.18), MNKD: 6.18 (+0.10), ARNA: 4.61 (-0.09)

Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.38 (+0.11), OHRP: 7.45 (+0.18), REGN: 402.63 (+1.52)

Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
GlobeNewswire - Tue Oct 14, 6:15AM CDT
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
GlobeNewswire - Tue Oct 07, 7:02AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual acuity data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate podium sessions at the 2014 American Academy of Ophthalmology (AAO) Annual Scientific Meeting, being held in Chicago, Illinois, from October 17-21, 2014.
OHRP: 7.45 (+0.18)

Retinal Vein Occlusion - Pipeline Review, H2 2014 - 8 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3bmznr/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV - Ohr Pharmaceutical Inc. - Kala Pharmaceuticals, Inc. - Mabion SA Drug Profiles - fluocinolone acetonide - squalamine lactate - beclomethasone dipropionate - loteprednol etabonate - ranibizumab - ocriplasmin (recombinant) - NCX-434 - NCX-422 - AVA-101 - ranibizumab biosimilar For more information visit http://www.researchandmarkets.com/research/3b...tinal_vein
AGN: 196.21 (-0.30), OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
GlobeNewswire - Tue Sep 09, 8:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II clinical trial evaluating Squalamine eye drops (OHR-102) for the treatment of the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the Retina Society 47 Annual Scientific Meeting, being held in Philadelphia, Pennsylvania from September 11-14, 2014.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
GlobeNewswire - Wed Aug 13, 7:30AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study evaluating Squalamine Eye Drops (OHR-102) for the treatment of the wet form of age-related macular degeneration ("wet-AMD"

. The data demonstrated a visual acuity and anatomical benefit for the group of patients receiving the combination of OHR-102 and Lucentis PRN ("OHR-102 arm"

versus placebo eye drops plus Lucentis PRN ("Lucentis monotherapy arm"

. Jason Slakter, MD, retina specialist and Chief Medical Officer at Ohr, presented the data on Tuesday, August 12 at the 2014 Annual Meeting of the American Society of Retina Specialists ("ASRS"

.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
GlobeNewswire - Mon Aug 11, 8:59AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops (OHR-102) in the treatment of macular edema secondary to branch (BRVO) or central retinal vein occlusion (CRVO). The data demonstrated that the combination of topical Squalamine eye drops and intravitreal Lucentis(R) led to a mean gain in visual acuity ("VA"

of 20.3 letters and resolution of the fovial edema in 95% of the patients at week 10. John Wroblewski, MD, retina specialist at Cumberland Valley Retina Consultants, presented the 10 week data on Saturday, August 9 at the 2014 Annual Meeting of the American Society of Retina Specialists.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
GlobeNewswire - Fri Aug 08, 7:04AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will present a corporate overview and business update at the 2014 Wedbush Life Sciences Management Access Conference, being held at the Le Parker Meridien Hotel in New York City on August 12-13, 2014.
OHRP: 7.45 (+0.18)

Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
GlobeNewswire - Thu Aug 07, 8:32AM CDT
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating Squalamine eye drops for the treatment of macular edema secondary to central and branch retinal vein occlusion, and the wet form of age-related macular degeneration (wet AMD), will be presented in two separate sessions at the 2014 Annual Meeting of the American Society of Retina Specialists, being held at the Hilton Bayfront Hotel in San Diego, California.
OHRP: 7.45 (+0.18)

Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 8:19AM CDT
Can the Rally in OHR Pharmaceutical (OHRP) Shares Continue?
OHRP: 7.45 (+0.18)

4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Aug 01, 6:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
CRMD: 1.40 (-0.28), ACRX: 6.77 (-0.18), THLD: 3.01 (-0.13), OHRP: 7.45 (+0.18)

Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 7:44AM CDT
Anacor Pharmaceuticals, Inc. (ANAC) was a big mover last session, as the company saw its shares surge nearly 7% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), OHRP: 7.45 (+0.18), ANAC: 31.46 (-0.31)

Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox
at The Street - Fri Jul 18, 6:51AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
ACRX: 6.77 (-0.18), XBI: 171.34 (-2.34), OHRP: 7.45 (+0.18), NYMX: 0.49 (-0.09), ENTA: 43.22 (-0.09)

Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:44AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 7% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), OHRP: 7.45 (+0.18), GNCA: 8.94 (-0.06)

Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), LJPC: 11.06 (-2.08), OHRP: 7.45 (+0.18)

Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
SGYP: 3.07 (-0.08), BCRX: 10.39 (-0.39), AERI: 24.37 (-0.68), OHRP: 7.45 (+0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Landstar Faces Legal Storm Post Earnings Miss

Landstar's Earnings Misstep Sends Shockwaves Alright, let's talk about this snafu at Landstar (NASDAQ: LSTR). They were supposed to deliver an earnings sheet that's all roses, but instead, we got a couple of thorns. Analysts were expecting them to strike gold with EPS numbers between $1.62 to $1.67. What we got? A measly $1.42. Not exactly the shiny haul we were led to...

InventHelp's BLU MESH: A Breath of Fresh and Bug-Free Air

Breathing Fresh Air Without the Buzz Here's a fresh spin on driving with the windows down: avoiding bug invasions. We’ve all experienced it—the unexpected slap on the arm or that annoying buzz in your ear just as you're drifting into a long podcast. Thanks to an inventor from East Stroudsburg, Pa., there's an idea on the table for a vehicular add-on that might just...

$4 Million Raised at Miracles for Kids Gala 2026

Anthony Geisler's Impactful Philanthropy Ever heard that old chestnut about putting your money where your mouth is? Well, Anthony Geisler, the chap behind Sequel Brands, sure seems to embody it. At the 2026 Miracles for Kids Night of Miracles Gala, he managed to corral over $4 million for families with critically ill kids. That's no chump change, let me tell you. The...

Yeastar's AI Innovations Shine at Yeahs Awards 2026

Award Recap: The Best of Yeastar’s Yeahs 2026 Blasting out of the gates here with some hefty recognition at the Yeahs Awards 2026—Yeastar is slinging accolades like confetti at a wedding. What’s the deal? It’s all about their partners and their slick moves in Unified Communications (UC). These tech whizzes are racking up milestones in AI, cloud services, and...

Wabi's $1.25B Valuation: A New Era for AI?

By Logan Wright Updated Oct 29, 2026 Category News Views 155

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

Texas Community Bancshares Acquires SJCB for $9.5M

Texas Community Bancshares Makes a Bold Move In the gritty world of finance, where deals and dollars often rule over sentimentality, Texas Community Bancshares, Inc. (NASDAQ: TCBS) has decided it's game time by acquiring The Banc of San Jacinto County Bancshares, Inc. in a decisive all-cash transaction. Yep, they’re throwing $9.5 million cash on the table to grab a...

Dermatology Access Expands in Kansas With Expert Return

Jenna King's Return Elevates Local Care Who says you can't go home again? Jenna King, a familiar face in Southeast Kansas, is back to serve her community by upping the ante in dermatology care at U.S. Dermatology Partners in Pittsburg. After gaining experience in Oklahoma, she's here to extend both medical and cosmetic treatments to her neighbors. Why Her Return Is a Game...

Airthereal Debuts ArcVac: A New Era in Pet-Friendly Cleaning

New Kid on the Block: ArcVac Changes the Game Alright, folks, just when I thought I've seen it all in the gizmo world, Airthereal pops up with their latest brainchild—the ArcVac Touchless Vacuum Automatic Dustpan. It's quite a mouthful, but this tool might just be every pet owner's new best buddy. This sleek little number ain't your grandma's dustpan. It's a whole new...

KLX Energy Refreshes Board with Seasoned Directors

A New Chapter for KLX Energy Services KLX Energy Services has just reshuffled its board, and it's stirring interest. With Franklin S. Edmonds, Jr. and E. Dirk Hallen stepping into the roles of independent directors, effective October 29, 2026, there's change in the air. They take over from John Collins and Tom McCaffrey, who've been holding the fort during some...

Meitu Sees Soaring Subscriber Growth Amid AI Focus

Subscriber Growth Hits a Record High Well, here's a headline to chew on—Meitu, Inc. is boasting a whopping 19.83 million paying subscribers, setting a new milestone. That's 1.39 million new users this quarter alone, the most significant uptick they've seen in four cycles. Not that I'm surprised; when you've got a product mix like theirs that's riding high on the wave of...